An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new clinic in Silicon Valley, NexGen Health, is now offering intravenous (IV) treatments with a product called Cerebrolysin. The announcement comes from a company press release and advertises that people can receive this therapy at their facility. The release doesn’t present new scientific proof; it’s primarily informing the public that the service is available at that location. Cerebrolysin is a mixture of small protein fragments called peptides and other components derived from pig brain tissue. It’s sold in some countries as a treatment that supporters say can protect and support brain cells. In simple terms: proponents describe it as a cocktail of tiny molecules that might help nerve cells survive or work better. It is not a single, well-defined drug like aspirin, and its exact makeup is a complex biological extract. What the press release does not do is present rigorous new clinical trial data. Cerebrolysin has been studied mostly outside the United States in a range of conditions, including after strokes, in traumatic brain injury, and in dementia. Results across studies are mixed: some small trials and reviews have reported benefits, while others find little or no clear effect. The announcement about availability at NexGen Health is a service update, not evidence that Cerebrolysin reliably improves cognition or recovery in well-designed large trials. If you want to know whether it works for a specific condition, you’d need to look at large, peer-reviewed studies rather than a clinic’s press release. Why this matters is practical: people in Silicon Valley and nearby can now get IV Cerebrolysin locally if they choose to pursue it. That could appeal to patients exploring experimental or off-label therapies for cognitive issues, aging concerns, or recovery after brain injury. For someone who has exhausted standard treatments or wants to try additional options, the local availability removes travel barriers. It also means clinicians and patients should have clear conversations about what the therapy can and cannot be expected to do, and about costs, because availability doesn’t equal proven benefit. There are important caveats and risks. Cerebrolysin’s regulatory status varies by country; in the U.S., it has not been approved by the FDA as a standard treatment for most neurological conditions, which affects how it is prescribed and monitored. As an IV treatment, it carries risks typical of infusions: allergic reactions, infection at the injection site, and other side effects. The long-term safety profile is not conclusively established for many uses. Anyone thinking about this therapy should consult a qualified neurologist or other specialist, ask for the evidence for the specific condition, and understand potential costs and unknowns. Bottom line: NexGen Health is offering Cerebrolysin IVs locally, but availability is not the same as strong proof of benefit — do your homework and talk to a specialist before considering it.
Source: PR Newswire